More from BEACON CRC & TAILOR
Josep Tabernero: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab
Conclusions: In BEACON CRC triplet and doublet showed encouraging activity in BRAFV600E mCRC. Data suggest that the triplet offers improved efficacy vs doublet with some additional manageable toxicity and no impact on overall QOL. Further follow-up will better define the relative benefits of the regimens.
NEJM: S. Kopetz and Others: Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Shukui Qin et al. Impact of primary tumor side on 3-year survival outcomes of first-line (1L) FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial
Conclusions: This updated analysis at > 4.5 years’ median follow-up is consistent with previous results from the TAILOR study, which showed improved OS with the addition of cetuximab to FOLFOX-4. Indeed, the 3-year OS rate was doubled in patients with L-sided mCRC and > 1.5 times higher in those with R-sided disease, showing that patients with mCRC might benefit from treatment with cetuximab irrespective of primary tumor side. Overall, these results confirm cetuximab in combination with FOLFOX-4 as an effective standard-of-care 1L therapy for patients with RAS wt mCRC.